Skip to content

AnaptysBio

US · ANAB #3010 by market cap Listed 2017
46.63 -0.77 -1.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 47.00 -0.84%
After-hours 46.63 0.00%
69.8145.4346.632026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ANAB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +34.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 16.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation B-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 9.0x Better than 85%
Forward P/E 9.5x Better than 83%
Price / Sales 5.9x Better than 18%
P/E vs own 5-yr range 93rd pctl Better than 11%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability B-

How much profit the business keeps from each dollar of sales and capital.

Operating margin 20.4% Better than 77%
Net margin -5.6% Better than 19%
Return on equity -24.5% Better than 15%
Return on invested capital 52.4% Better than 99%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -19.2% Better than 32%
6-month return -21.9% Better than 25%
12-month return (ex latest month) 84.5% Better than 93%
Distance below 52-week high 35.6% Better than 34%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.1x Better than 93%
Debt to assets 3.9% Better than 82%
Interest coverage 0.8x Better than 28%
Free cash flow / net income 409.3% Better than 91%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 71.6% Better than 76%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +0.82%
1M +2.64%
3M -17.75%
6M -22.39%
YTD +44.28%
1Y +85.73%
3Y +382.05%
5Y +127.09%

Key statistics

Price & volume

Prev close
47.40
Open
47.49
Day range
46.05 - 47.71
Avg price
46.72
Volume
432.45K
Turnover
20.21M
Amplitude
3.50%
52-week range
26.01 - 72.36

Valuation

P/E
8.33
P/E (TTM)
8.98
P/B
66.61
EPS
5.60
Net profit
166.49M
Net assets
20.81M

Share structure

Market cap
1.39B
Float cap
948.03M
Shares out
29.73M
Float shares
20.33M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-01-26
52-week range 44% of range
26.01 72.36

35.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-612.54K net over the window

Short interest

Shares short
5.05M
As of
2026-10-30

Frequently asked questions

What is the current stock price of AnaptysBio (ANAB)?

AnaptysBio last traded at 46.63. This page shows a periodic quote snapshot. Check the displayed quote time.

What is AnaptysBio's market cap?

About 1.39B.

What is the P/E ratio of AnaptysBio?

The trailing twelve-month P/E is 8.98. The Valuation tab shows it against the stock's own five-year range.

Does AnaptysBio pay a dividend?

AnaptysBio does not currently pay a regular dividend.

Is AnaptysBio a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 80.00, which implies 71.6% upside from the current price. This is not investment advice.

What is AnaptysBio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates AnaptysBio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

AnaptysBio discussion 0 comments

Add a comment